DOCSLIB.ORG

Cinacalcet for the Treatment of Calciphylaxis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cinacalcet for the Treatment of Calciphylaxis THE CUTTING EDGE SECTION EDITOR: GEORGE J. HRUZA, MD; ASSISTANT SECTION EDITORS: MICHAEL P. HEFFERNAN, MD; SUMMER R. YOUKER, MD Cinacalcet for the Treatment of Calciphylaxis Maria R. Robinson, MD; Joshua J. Augustine, MD; Neil J. Korman, MD, PhD; Departments of Dermatology (Drs Robinson and Korman) and Medicine, Division of Nephrology and Hypertension (Dr Augustine), University Hospitals Case Medical Center, Cleveland, Ohio The Cutting Edge: Challenges in Medical and Surgical Therapeutics Calciphylaxis is characterized by cutaneous ischemia standing Crohn disease that required an ileostomy and and necrosis and is associated with a very high mortality end-stage renal disease that had resulted in a kidney trans- rate. It usually affects patients who are undergoing dialy- plant 2 years prior to presentation. During his hospital- sis or who have received a kidney transplant. There is no ization, the dermatology department was consulted be- optimal treatment, but parathyroidectomy has shown cause the patient had painful bilateral thigh ulcers, which some benefit. We report herein a case of a patient with had developed 4 months prior to admission. calciphylaxis and secondary hyperparathyroidism who was successfully treated with cinacalcet hydrochloride, a See also page 269 calcimimetic. On initial examination, the patient had a 3.0ϫ4.0-cm ulcer with eschar and surrounding induration and vio- REPORT OF A CASE laceous discoloration on his right thigh. On his left thigh, there was a 2.5-cmϫ4.0-mm linear hemorrhagic crust. A 62-year-old man was admitted to the hospital for gas- In addition, he had violaceous discoloration in a livedo trointestinal bleeding and was found to have an el- reticularis pattern over his lower extremities bilaterally. evated international normalized ratio. The patient had a Laboratory evaluation on admission included the fol- medical history of chronic nephrolithiasis from long- lowing findings: his calcium level was 7.9 mg/dL (2.0 mmol/L); phosphorus level, 5.5 mg/dL (1.8 mmol/L); al- bumin level, 3.3 g/dL; urea nitrogen level, 39 mg/dL (13.9 mmol/L); creatinine level, 4.0 mg/dL (305.0 µmol/L); in- tact parathyroid hormone level, 1080 pg/mL (reference range, 7-53 pg/mL); 25-hydroxyvitamin D level, 10.0 ng/mL (25.0 nmol/L) (reference range, 20-57 ng/mL [49.9- 142.3 ng/mL]); and 1,25-dihydroxyvitamin D level, 11.1 pg/mL (28.9 pmol/L) (reference range, 15.9-55.6 pg/ml [41.3-144.6 pmol/L]). The calcium-phosphorus prod- uct was 43.5 mg/dL. Findings from an excisional biopsy of the right thigh ulcer showed focal ulceration with fi- brinoid and hemorrhagic exudate. There were also nu- merous small vessel thrombi and deposits of calcium pres- ent within the deep blood vessel walls. These histologic findings indicated a diagnosis of calciphylaxis. The patient was treated with silver sulfadiazine cream twice a day with aggressive wound care for the ulcers, vitamin D therapy, and phosphorus binders. The pa- tient’s hypocalcemia and hyperphosphatemia improved with therapy. Although his persistently elevated para- thyroid hormone level improved, there was no improve- ment in his wounds. Parathyroid imaging was negative for parathyroid adenoma. His elevated international nor- malized ratio was corrected with vitamin K supplemen- tation, and he was discharged from the hospital. One month later, his wounds had increased in size, with the right thigh ulcer increasing to 5ϫ9 cm and the left thigh ulcer to 3ϫ6cm(Figure 1). On his poste- Figure 1. Large ulcer on the left thigh with eschar and surrounding erythema rior calves bilaterally, there were tender, erythematous, and induration before treatment with cinacalcet hydrochloride. and indurated plaques ranging in size from 1 to 3 cm. (REPRINTED) ARCH DERMATOL/ VOL 143, FEB 2007 WWW.ARCHDERMATOL.COM 152 ©2007 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/26/2021 Table. Patient Laboratory Values Over the Course of Several Months* Date, Parathyroid Calcium, Phosphorous, 2005-2006 Hormone, pg/mL mg/dL mg/dL April 1 1080 7.9 5.5 May 6 684 8.8 4.1 October 18 550 8.7 4.5 December 13 408 7.8 4.2 February 7 147 7.6 3.9 SI conversion factors: To convert calcium to millimoles per liter, multiply by 0.25; to convert phosphorous to millimoles per liter, multiply by 0.323. *Therapy with cinacalcet hydrochloride was started in May. The reference range for parathyroid hormone is 7 to 53 pg/mL; for calcium, 8.5 to 10.1 mg/dL; and for phosphorous, 2.5 to 4.5 mg/dL. THERAPEUTIC CHALLENGE Calciphylaxis is characterized by progressive vascular cal- cium deposition and cutaneous ischemia and necrosis and usually affects patients with end-stage renal disease who are undergoing hemodialysis or have received a kidney transplant. Although there is no optimal treatment for calciphylaxis, there have been several reports of benefi- cial treatment using different modalities. These include low-dose tissue plasminogen activator,1 parathyroidec- 2-4 5,6 7 Figure 2. Left thigh ulcer after 5 months of treatment with cinacalcet tomy, hyperbaric oxygen, wound debridement, in- hydrochloride. travenous sodium thiosulfate,8 low-molecular-weight hep- arin,9 increased frequency of hemodialysis,10 and using 3-cm ulcers over his lower extremities. Three of these a zero-calcium dialysate.11 wounds healed, and the fourth did not become larger. Our patient presented with clinical and histopatho- After 5 months of treatment, the dosage of cinacalcet hy- logic evidence of calciphylaxis. He also had secondary drochloride was increased to 60 mg/d, and his parathy- hyperparathyroidism induced by his end-stage renal dis- roid hormone level continued to decline. His last mea- ease. His parathyroid hormone levels were as high as 1080 sured value was 147 pg/mL (Table). pg/mL. He was considered to be a high-risk surgical can- didate for parathyroidectomy, and continued wound care COMMENT did not halt the progression of disease. The prevalence of calciphylaxis has been estimated to be SOLUTION approximately 4% in patients who are undergoing hemo- dialysis,16 and mortality estimates are as high as 87%.9 Prog- Parathyroidectomy prolongs survival in some patients nosis has been shown to vary with lesion distribution, with with calciphylaxis,2-4 but its role is still controver- survival rates ranging from 25% for proximal lesions and sial.12,13 Parathyroidectomy both lowers parathyroid hor- 75% for distal lesions.2 The pathogenesis of calciphylaxis mone levels and helps restore normal calcium and phos- (also referred to as uremic small-artery disease with me- phorous homeostasis, helping to reduce known risk dial calcification and intimal hyperplasia, uremic small- factors for calciphylaxis.14 Because this patient was a high- vessel disease, uremic gangrene syndrome, and calcific ure- risk surgical candidate, medical treatment with cinacal- mic arteriolopathy) is incompletely understood. Several cet, a calcimimetic that has lowered parathyroid levels risk factors have been identified, including secondary hy- in patients receiving hemodialysis,15 was started. The pa- perparathyroidism,17 increased serum phosphate and cal- tient received a daily dose of 30 mg of cinacalcet hydro- cium ϫ phosphate product, female sex, diabetes melli- chloride. tus,14 and protein C deficiency.18 Several weeks after the initiation of therapy with cina- Parathyroid hormone, the main regulator of calcium calcet, the patient reported less pain associated with the homeostasis, is affected by calcium, phosphorous, and ulcers, and his parathyroid hormone level continued to 1,25-dihydroxyvitamin D3 levels. In patients with renal decline (Table). On physical examination, the right thigh failure, there is an impaired ability to clear phospho- wound showed dramatic improvement with re- rous and an impaired synthesis of 1,25-dihydroxyvita- epithelialization of the ulcer, and the left thigh wound min D3, which result in hyperphosphatemia and de- also began to heal. Five months after he began treat- creased calcium absorption. These elements contribute ment with cinacalcet, both ulcers continued to heal and to the development of secondary hyperparathyroidism, the patient noted symptomatic improvement (Figure 2). which is common in patients undergoing hemodialy- During this time, the patient did develop 4 smaller 1- to sis.19,20 In addition, a deficiency in vitamin D can exac- (REPRINTED) ARCH DERMATOL/ VOL 143, FEB 2007 WWW.ARCHDERMATOL.COM 153 ©2007 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/26/2021 erbate secondary hyperparathyroidism. The medical treat- tomy promotes wound healing and prolongs survival in patients with calciphy- ment of secondary hyperparathyroidism includes control laxis from secondary hyperparathyroidism. Surgery. 2001;130:645-651. 21 4. Arch-Ferrer JE, Beenken SW, Rue LW, Bland KI, Diethelm AG. Therapy for cal- of hyperphosphatemia and therapy with calcitriol. Lev- ciphylaxis: an outcome analysis. Surgery. 2003;134:941-945. els of parathyroid hormone are not uniformly elevated 5. Vassa N, Twardowski ZJ, Campbell J. Hyperbaric oxygen therapy in calciphylaxis- in patients with calciphylaxis, and some physicians have induced skin necrosis in a peritoneal dialysis patient. Am J Kidney Dis. 1994; recommended parathyroidectomy only for patients with 23:878-881. 6. Podymow T, Wherrett C, Burns KD. Hyperbaric oxygen in the treatment of cal- intractable secondary hyperparathyroidism uncon- ciphylaxis: a case series. Nephrol Dial Transplant. 2001;16:2176-2180. 21,22 trolled by medical means. 7. Kang AS, McCarthy JT, Rowland C, Farley DR, Van Heerden JA. Is calciphylaxis To treat the patient’s secondary hyperparathyroid- best treated surgically or medically? Surgery. 2000;128:967-972. ism with very high levels of parathyroid hormone, therapy 8. Cicone JS, Petronis JB, Embert CD, Spector DA. Successful treatment of calci- with cinacalcet, a class II calcimimetic that targets the phylaxis with intravenous sodium thiosulfate.
Load more

Recommended publications
  • A Case of Calciphylaxis with an Unfavorable Outcome
    CASE LETTER 671 However, the present patient exhibited the peculiarity References of an intense inflammatory infiltrate in the dermis rarely seen previously. According to this case, an atypical intense 1. Sitaru C, Zillikens D. Mechanisms of blister induction by autoan- inflammation could be a distinct histopathological feature tibodies. Exp Dermatol. 2005;14:861---75. of trauma-induced pemphigus. Further research is neces- 2. Sagi L, Trau H. The Koebner phenomenon. Clin Dermatol. sary to ascertain if greater inflammation in dermis is more 2011;29:231---6. related to trauma-induced pemphigus as opposed to those 3. Jang HW, Chun SH, Lee JM, Jeon J, Hashimoto T, Kim IH. Radiotherapy-induced pemphigus vulgaris. J Dermatol. not related to trauma. 2014;41:851---2. In conclusion, this report describes a presumably new 4. Daneshpazhooh M, Fatehnejad M, Rahbar Z, Balighi K, case of trauma-induced pemphigus. To the author’s knowl- Ghandi N, Ghiasi M, et al. Trauma-induced pemphigus: a edge, there are no prior reports of pemphigus involving case series of 36 patients. J Dtsch Dermatol Ges. 2016;14: predominantly the breasts with such a peculiar dispo- 166---71. sition. It is proposed that a hypothetical continuous 5. Balighi K, Daneshpazhooh M, Azizpour A, Lajevardi V, trauma with the bra could explain this unique loca- Mohammadi F, Chams-Davatchi C. Koebner phenomenon tion. in pemphigus vulgaris patients. JAAD Case Rep. 2016;2: 419---21. Financial support Fernando Garcia-Souto None declared. Department of Dermatology, Valme University Hospital, Seville, Spain Author’s contributions E-mail: [email protected] Received 14 November 2019; accepted 5 March 2020 Fernando Garcia-Souto: Conception and planning of the manuscript; writing and critical revision of the manuscript; https://doi.org/10.1016/j.abd.2020.03.010 approval of the final version.
    [Show full text]
  • Extensive Skin Necrosis Ulcers and Systemic Vascular Insufficiency Syndrome with Calciphylaxis: a Case Report
    Urology & Nephrology Open Access Journal Case Report Open Access Extensive skin necrosis ulcers and systemic vascular insufficiency syndrome with calciphylaxis: a case report Abstract Volume 5 Issue 4 - 2017 Calciphylaxis is a part of systemic vascular calcification that is commonly seen in patients 1 2,3 with end stage renal disease. It presents as skin ischemia and necrosis due to calcification Alexander M Swan, Nancy J Fried, 2,3 2 of dermal arterioles. There is no consensus on optimal treatment and the condition is Charisma Lee, Thein Aung, Zaw Nyein associated with a high mortality rate. Here we report a patient on peritoneal dialysis with Aye,2 Deepthi Gunasekaran2 a high calcium-phosphorus product and extensive calciphylaxis involving the extremities, 1Wilkes University, USA back and scalp. We used a multi-interventional approach to treat this patient with a good 2Nephrology Hypertension Renal transplant and Renal Therapy, outcome. The underlying pathology of systemic vascular calcification and insufficiency USA 3 may involve other vascular beds such as the coronary and cerebral vasculature. Early Rutgers New Jersey Medical School, USA detection of these conditions may improve outcomes in these patents. Correspondence: Alexander M Swan, AA Prof of Medicine, Keywords: necrotic ulcer of skin, calciphylaxis, calcium-phosphorus product, vascular Rutgers New Jersey Medical School, 185 S Orange Ave, Newark, calcification, systemic vascular insufficiency NJ 07103, President, Garden State Kidney Center, 345 Main Street, Woodbridge, NJ 07095, USA, Tel 732-750-5555, Fax 732- 750-5550, Email Received: November 10, 2017 | Published: October 26, 2017 Abbreviations: ESRD, end-stage renal disease; CUA, calcific secondary to hypertension and peritoneal dialys is was initiated 5years uremic arterilopathy; LMWH, low molecular weight heparin ago after multiple access problems with hemodialysis.
    [Show full text]
  • AACE Annual Meeting 2021 Abstracts Editorial Board
    June 2021 Volume 27, Number 6S AACE Annual Meeting 2021 Abstracts Editorial board Editor-in-Chief Pauline M. Camacho, MD, FACE Suleiman Mustafa-Kutana, BSC, MB, CHB, MSC Maywood, Illinois, United States Boston, Massachusetts, United States Vin Tangpricha, MD, PhD, FACE Atlanta, Georgia, United States Andrea Coviello, MD, MSE, MMCi Karel Pacak, MD, PhD, DSc Durham, North Carolina, United States Bethesda, Maryland, United States Associate Editors Natalie E. Cusano, MD, MS Amanda Powell, MD Maria Papaleontiou, MD New York, New York, United States Boston, Massachusetts, United States Ann Arbor, Michigan, United States Tobias Else, MD Gregory Randolph, MD Melissa Putman, MD Ann Arbor, Michigan, United States Boston, Massachusetts, United States Boston, Massachusetts, United States Vahab Fatourechi, MD Daniel J. Rubin, MD, MSc Harold Rosen, MD Rochester, Minnesota, United States Philadelphia, Pennsylvania, United States Boston, Massachusetts, United States Ruth Freeman, MD Joshua D. Safer, MD Nicholas Tritos, MD, DS, FACP, FACE New York, New York, United States New York, New York, United States Boston, Massachusetts, United States Rajesh K. Garg, MD Pankaj Shah, MD Boston, Massachusetts, United States Staff Rochester, Minnesota, United States Eliza B. Geer, MD Joseph L. Shaker, MD Paul A. Markowski New York, New York, United States Milwaukee, Wisconsin, United States CEO Roma Gianchandani, MD Lance Sloan, MD, MS Elizabeth Lepkowski Ann Arbor, Michigan, United States Lufkin, Texas, United States Chief Learning Officer Martin M. Grajower, MD, FACP, FACE Takara L. Stanley, MD Lori Clawges The Bronx, New York, United States Boston, Massachusetts, United States Senior Managing Editor Allen S. Ho, MD Devin Steenkamp, MD Corrie Williams Los Angeles, California, United States Boston, Massachusetts, United States Peer Review Manager Michael F.
    [Show full text]
  • Understanding Calcinosis and Calciphylaxis
    PRACTICE DEVELOPMENT Understanding calcinosis and calciphylaxis KEY WORDS Calcinosis cutis is a rare cause of non-healing leg ulceration. There are many factors Calcinosis cutis that can delay the healing of venous leg ulceration and the deposition of calcium in Calciphylaxis the skin known as calcinosis cutis is one of these factors. There are five distinct forms: Warfarin-induced skin dystrophic calcification, metastatic calcification, idiopathic calcification, iatrogenic necrosis calcification and calciphylaxis. Warfarin skin necrosis has common clinical features with calciphylaxis and is therefore included in this article, which describes the types of calcinosis cutis, their clinical presentations and limited treatment options. The aim is to highlight these unusual causes and to assist healthcare professionals when faced with a non-healing ulcer. eg ulceration can be defined as a defect in neurotransmission and the blood coagulation the dermis located on the leg (Franks et al, pathway. At a cellular level, it is implicated in 2016). Leg ulceration is a significant clinical cell-to-cell communication (Walshe and Fairley, Lproblem with the majority attributing venous 1995). In the skin, it is specifically concerned with hypertension as the underlying disease process with keratinocyte proliferation, differentiation and venous leg ulceration affecting 1% of the population adhesion (Smith and Yamada, 2002). in the western world (Posnett et al, 2009). However, The level of serum calcium is closely there is a multitude of causative factors of leg ulcers, controlled by the parathyroid hormone. with the term leg ulcer purely signifying the clinical Regardless of this regulation, it is possible for manifestation and not the underlying aetiology.
    [Show full text]
  • 95F325afe6daa80601f51b046b3
    D.M. DEGREE EXAMINATIONEPHROLOGY-PAPER - I Basic Sciences And Applied Nephrology 30 m 1) Discuss renal acid handling and pathomechanism of renal tubular acidosis 2) Discuss the role of ‘Klotho – FGF 23 complex’ in health and chronic kidney disease 3) Enumerate causes for hypokalemia and describe in detail about potassium homeostasis 4) The ageing kidney 5) Discuss the role of complement in renal disease 6) Discuss in detail the pathogenesis of membranous glomerulonephritis and its management 7) Discuss the etiopathogenesis of the syndrome of inappropriate secretion of anti diuretic hormone. How can it be recognized and managed? 8) Describe Nephron dosing and its clinical relevance 9) Discuss the relevant physiological changes of pregnancy and pathogenesis of toxemia of Pregnancy 10) Discuss in brief Physiology of Vitamin D, vitamin D analogues and their role in nephrology practice 11) Discuss the pathogenesis, evaluation and management of disorders of micturition 12) Discuss in brief embryological development of the kidney and its clinical relevance 13) Discuss renal handling of sodium and diagnostic approach to hyponatremia 14) Discuss aetiology, pathogenesis, clinical features and management of hepato renal syndrome 15) Discuss the etiopathogenesis of the syndrome of inappropriate secretion of anti diuretic hormone. How can it be recognized and managed? 16) Describe the etiology, clinical manifestations, diagnosis & management of metabolic alkalosis 17) Describe the mechanism and types of proteinuria. What are the therapeutic interventions that may be used to reduce proteinuria 18) Describe the renin-angiotensin system and its physiologic role. Discuss its role in the pathophysiology of renal disease 19) Discuss pathophysiology of proteinuria, classify proteinuria, name diseases which produces different types of proteinuria.
    [Show full text]
  • A Fatal Complication Not Only in End-Stage Renal Disease Patients
    PRACA KAZUISTYCZNA Folia Cardiologica 2020 tom 15, nr 2, strony 164–168 DOI: 10.5603/FC.2020.0022 Copyright © 2020 Via Medica ISSN 2353–7752 Calciphylaxis — a fatal complication not only in end-stage renal disease patients Kalcyfilaksja — śmiertelne powikłanie nie tylko u pacjentów ze schyłkową niewydolnością nerek Ada Bielejewska1●iD, Arkadiusz Bociek1●iD, Andrzej Jaroszyński1, 2●iD 1Collegium Medicum, Jan Kochanowski University, Kielce, Poland 2Nephrology Clinic, Provincial Integrated Hospital in Kielce, Poland Abstract We present a fatal case of the end-stage renal disease complication that is calciphylaxis. Also known as calcific uremic arteriolopathy, it is characterised by vascular calcification, necrosis of the skin and adipose tissue, and constant severe pain of the affected areas. Key words: calciphylaxis, calcific uremic arteriolopathy, end-stage renal disease, complications Folia Cardiologica 2020; 15, 2: 164–168 Introduction some cancers (treated with chemotherapy), liver cirrhosis, and autoimmune diseases. Risk factors of calciphylaxis Calciphylaxis, also known as calcific uremic arteriolopathy include, among others, haemodialysis, female sex, obesi- (CUA), is a rare disease with an estimated annual incidence ty, diabetes mellitus, Caucasian ethnicity, hypercalcemia, ranging from 1 to 35 in every 10,000 haemodialysed pa- hyperphosphatemia, hyperparathyroidism (both primary tients worldwide [1]. Its pathogenesis in unclear. Calciphyla- and secondary), adynamic bone disease, elevated al- xis affects small vessels of the skin and fatty tissue, as cal- kaline phosphatase, autoimmune diseases, hypoalbu- cium deposits accumulate within their walls. This, together minemia, genetic polymorphisms, abnormalities within with thrombotic occlusion, leads to ischaemic necrosis of the coagulation system, recurring skin trauma (e.g. from the skin that causes severe pain within the affected areas subcutaneous injections) and medications (e.g.
    [Show full text]
  • A Case of Calciphylaxis and Chronic Myelomonocytic Leukemia
    A Case of Calciphylaxis and Chronic Myelomonocytic Leukemia Heather W. Goff, MD; Ronald E. Grimwood, MD A 70-year-old woman presented for evaluation of trauma as physiologic challengers in calciphylaxis in symmetric necrotic ulcers of the lower extremities. humans as well.5-7 Biopsy results revealed changes consistent with calciphylaxis. The predisposing factors in this Case Report patient included calcium supplementation, obe- A woman came to our hospital for a second opinion sity, female gender, viscous blood, renal failure, regarding symmetric necrotic ulcers with central and diabetes mellitus. To our knowledge, this is leathery eschar and surrounding violaceous erythema the first report of calciphylaxis occurring in the and bullae on the inferior and posterior aspects of setting of chronic myelomonocytic leukemia. We both lower extremities; these lesions had begun discuss the history, clinical presentation, diagno- developing 3 weeks earlier (Figure 1). According to sis, and treatment of calciphylaxis. the patient’s history, the lesions were initially Cutis. 2005;75:325-328. painful, hard, lumpy areas, which eventually pro- ceeded to break down into small individual viola- ceous papules with central ischemic ulceration; the alciphylaxis involves a pathologic calcifica- papules gradually eroded from about 1 cm to larger tion of nonosseous tissue for which neither than 10 cm in diameter. C hypercalcemia nor hyperphosphatemia is The patient also had risk factors for calciphy- necessary. The condition results in calcification of laxis, including calcium supplementation, obesity, subcutaneous arterioles and infarctions of subcuta- female gender, viscous blood, renal failure, and neous adipose tissue. Although the etiology of cal- diabetes mellitus. In addition, the patient had a ciphylaxis is unclear, many predisposing factors history of chronic myelomonocytic leukemia, hypo- have been identified.1-3 thyroidism, and recent colon cancer resection.
    [Show full text]
  • Calciphylaxis
    Postgrad Med J 2001;77:557–561 557 Postgrad Med J: first published as 10.1136/pmj.77.911.557 on 1 September 2001. Downloaded from REVIEWS Calciphylaxis R V Mathur, J R Shortland, A M El Nahas Abstract phosphate diet act as sensitising agents result- The phenomenon of calciphylaxis is rare, ing in a high calcium-phosphate product (Ca × but potentially fatal. It has been recog- P; normal range 4.2–5.6 mmol2/l2) with result- nised for a long time in patients with ant precipitation of Ca-P crystals.14 This results chronic renal failure with secondary hy- in diVuse calcification of the media and perparathyroidism. Disturbed calcium internal elastic lamina of small to medium and phosphate metabolism can result in sized arteries and arterioles with intimal prolif- painful necrosis of skin, subcutaneous tis- eration and rarely arterial occlusion causing sue and acral gangrene. Appearance of the tissue necrosis. This entity was given the term lesions is distinctive but the pathogenesis calcinosis cutis to signify vascular calcification remains uncertain. The beneficial eVects with ischaemic epidermolysis as seen in of parathyroidectomy are controversial. patients with chronic renal failure on However, correction of hyperphosphatae- haemodialysis.15–17 Other triggering events in- mia or occasionally hypercalcaemia is clude intravenous iron dextran and albumin imperative. Fulminant sepsis as a conse- infusion, low serum albumin, corticosteroids, quence of secondary infection of necrotic immunosuppression, trauma, subcutaneous in- and gangrenous tissue is a frequent cause jections in obese patients, and protein C and S of patient morbidity and mortality. deficiencies causing hypercoagulability and 8 12 16 18–25 (Postgrad Med J 2001;77:557–561) subsequent thrombosis.
    [Show full text]
  • Dermatology Grand Rounds 2019 Skin Signs of Internal Disease
    Dermatology Grand Rounds 2019 skin signs of internal disease John Strasswimmer, MD, PhD Affiliate Clinical Professor (Dermatology), FAU College of Medicine Research Professor of Biochemistry, FAU College of Science Associate Clinical Professor, U. Miami Miller School of Medicine Dermatologist and Internal Medicine “Normal” abnormal skin findings in internal disease • Thyroid • Renal insufficiency • Diabetes “Abnormal” skin findings as clue to internal disease • Markers of infectious disease • Markers of internal malignancy risk “Consultation Cases” • Very large dermatology finding • A very tiny dermatology finding Dermatologist and Internal Medicine The "Red and Scaly” patient “Big and Small” red rashes not to miss The "Red and Scaly” patient • 29 Year old man with two year pruritic eruption • PMHx: • seasonal allergies • childhood eczema • no medications Erythroderma Erythroderma • Also called “exfoliative dermatitis” • Not stevens-Johnson / toxic epidermal necrosis ( More sudden onset, associated with target lesions, mucosal) • Generalized erythema and scale >80-90% of body surface • May be associated with telogen effluvium It is not a diagnosis per se Erythroderma Erythroderma Work up 1) Exam for pertinent positives and negatives: • lymphadenopathy • primary skin lesions (i.e. nail pits of psoriasis) • mucosal involvement • Hepatosplenomagaly 2) laboratory • Chem 7, LFT, CBC • HIV • Multiple biopsies over time 3) review of medications 4) age-appropriate malignancy screening 5) evaluate hemodynamic stability Erythroderma Management 1)
    [Show full text]
  • Fast Facts Core Curriculum Renal
    ! Fast Facts Core Curriculum Renal #114 Myoclonus . 2-3 #133 Non-Oral Hydration in Palliative Care. 4-5 #134 Non-Oral Hydration Techniques in Palliative Care . .6-7 #161 Opioid Use in Renal Failure . 8-9 #163 Decision Making in Chronic Kidney Disease . 10-11 #191 Prognostication in Patients Receiving Dialysis . 12-14 #207 Withdrawal of Dialysis: Decision- Making . .15-16 #208 Clinical Care Following Withdrawal of Dialysis . 17-18 #220 Hypodermoclysis . 19-21 #287 Drug-Induced Acute Urinary Retention . 22-24 #313 Thirst in Palliative Care . 25-27 !1 #325 Uremic Calciphylaxis . .28-30 #337 Palliation of Bladder Spasms . 31-33 !2 ! FAST FACTS AND CONCEPTS #114 MYOCLONUS Nicholas DeMonaco and Robert Arnold MD Background Myoclonus is an abnormal movement described as a sudden, brief, shock-like, involuntary movement caused by active muscle contraction (positive myoclonus) or inhibition of ongoing muscle contraction (negative myoclonus). Myoclonus can have a distribution that is focal, multifocal, or generalized. This Fast Fact discusses its causes, evaluation, and therapy. Characteristics and Differential Diagnosis Hiccups are an example of normal, physiological positive myoclonus, while asterixis is an example of negative myoclonus seen with metabolic encephalopathy. In nocturnal myoclonus or periodic leg movement disorder, there is activity in the flexor muscles of the legs and feet during light sleep. It can be seen in the setting of chronic nervous system diseases or in elderly patients with no other abnormalities. The brief, shock-like movements of myoclonus may be difficult to distinguish from other involuntary movements such as cramps, spasms, fasciculations, and dystonia. Fasciculations are brief involuntary muscle twitches that, unlike myoclonus, often do not result in movement across a joint.
    [Show full text]
  • Calciphylaxis in Renal Substitution Therapy Calcifilaxis En Terapia De Sustitución Renal
    Rev. Colomb. Nefrol. 2019;6(1): 68-72, january – june 2019 http://www.revistanefrologia.org Rev. Colomb. Nefrol. 2019;6(1): 68-72Cas, eneroe - junireporto de 201 9 http://www.revistanefrologia.org doi: http://dx.doi.org/10.22265/acnef.6.1.327http:/ /dx.doi.org/10.22265/acnef.6.1.327 Calciphylaxis in renal substitution therapy Calcifilaxis en terapia de sustitución renal Diego Alexander Mendoza Panta, Jorge Washington Huertas Garzón, Washington Xavier Osorio Chuquitarco Servicio de Nefrología, Hospital de Especialidades FF. AA. No. 1. Quito, Ecuador Abstract Calciphylaxis is one of the less common complications of Chronic Advanced Kidney Disease, especially in renal replacement therapy, the exact pathophysiology of its appearance is unknown, but it is believed that it is due to an alteration in bone-mineral metabolism. We describe a clinical case of a patient with chronic kidney disease, who presented as a serious complication calciphylaxis, reaching this diagnosis thanks to the characteristic images of this pathology taken from the bank of the Hospital’s imaging service. In conclusion, calciphylaxis, despite being a pathology difficult to find nowadays due to better control of bone-mineral metabolism, should be considered especially in those patients with rapid progression of renal disease and presence of suppurative calcified lesions in extremities. Key words: chronic kidney disease, calciphylaxis, bone-mineral metabolism, renal replacement therapy. doi: http://dx.doi.org/10.22265/acnef.6.1.327 Resumen La calcifilaxis es una de las complicaciones menos comunes de la enfermedad renal crónica avanzada, sobre todo en terapia de sustitución renal, se desconoce la fisiopatología exacta de aparición, pero se cree, que es por una alteración en el metabolismo óseo- mineral.
    [Show full text]
  • Electrolytes in the ICU Syed Zaidi, Rahul Bollam and Kainat Saleem
    Chapter Electrolytes in the ICU Syed Zaidi, Rahul Bollam and Kainat Saleem Abstract Electrolyte disorders is an imbalance of certain ionized salts (sodium, potassium, calcium, bicarbonate, chloride) in the blood. Healthcare providers should be famil- iar with the principles of electrolyte physiology and pathophysiology. Disturbances in sodium homeostasis are primarily caused by volume abnormalities leading to primarily neurologic symptoms. Dyskalemias frequently present with cardiac man- ifestations therefore should be treated promptly before evaluating its cause. Ion deficiencies such as hypocalcemia, hypomagnesemia and hypophosphatemia should be corrected as they are associated with increased adverse events in critically ill patients. Keywords: Electrolytes, Sodium, Potassium, critically ill, ICU 1. Introduction Electrolytes are elements that naturally occur in the human body and help balance pH, facilitate passage of fluid through osmosis and regulate the function of neuromuscular, endocrine and excretory systems. Disturbances in these electrolytes are common clinical problems encountered in the intensive care unit with serious complications when they are depleted. Recent studies report that electrolyte imbal- ances are associated with increased morbidity and mortality. Possible mechanisms include damage to the kidney, activation of hormonal systems (such as RAAS) or the myriad of medication given in a critically ill patient. This chapter will focus on various electrolyte abnormalities seen in the critical care setting then touch on important ICU scenarios which could affect electrolytes. 2. Disorders of sodium homeostasis • Serum sodium reflects the plasma tonicity and is inversely related to total body water. Changes in sodium are generally due to changes in total body water, not serum sodium, which regulates plasma tonicity and effective arterial volume.
    [Show full text]